|
PRESS RELEASES
|
13.02.2012 TILTAN PHARMA LAUNCHES PHASE II CLINICAL STUDY OF ITS ANTI-ANGIOGENIC PRODUCT TL-118 FOR THE TREATMENT OF PANCREATIC CANCER More Info |
|
22.06.2011 YISSUM ANNOUNCES TILTAN PHARMA TO BE ONE OF THE LEADING PORTFOLIO COMPANIES OF ITS NEW HOLDING COMPANY INTEGRA HOLDINGS Yissum, the technology transfer company of the Hebrew University of Jerusalem, announces Tiltan Pharma to be one of the leading portfolio companies of its new holding company Integra Holdings More Info |
|
07.02.2011 TILTAN PHARMA RECEIVES LARGEST CSO GRANT GIVEN TO A DRUG COMPANY FOR 2009: NIS 4.2M (ABOUT $1.2M) More Info |
|
21.12.2010 FDA APPROVES TILTAN’S INVESTIGATIONAL NEW DRUG (IND) CLINICAL TRIAL PROGRAM More Info |
|
09.09.2010 TILTAN PHARMA LTD. COMPLETES $2 MILLION FINANCING More Info |
|
26.04.2007 Globes Tiltan has developed an anti-cancer platform that attacks the cancer's supply line instead of the growth itself... More Info |